Dr. Lauren W. Veltri
Claim this profileWest Virginia University Healthcare
Studies Lymphoma
Studies Multiple Myeloma
5 reported clinical trials
10 drugs studied
Area of expertise
1Lymphoma
CCND1 positive
t(11;14) positive
2Multiple Myeloma
Stage III
Stage IV
Affiliated Hospitals
Clinical Trials Lauren W. Veltri is currently running
Lenalidomide + Dexamethasone +/- Daratumumab
for Multiple Myeloma
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.
Recruiting2 awards Phase 312 criteria
Lenalidomide +/- Daratumumab
for Multiple Myeloma
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment. Patients are treated for up to 7 years from Step 2 reg and followed for up to 15 years.
Recruiting2 awards Phase 317 criteria
More about Lauren W. Veltri
Clinical Trial Related4 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Lauren W. Veltri has experience with
- Lenalidomide
- Brentuximab Vedotin
- Nivolumab
- Ipilimumab
- Rituximab
- Autologous Hematopoietic Stem Cell Transplantation
Breakdown of trials Lauren W. Veltri has run
Lymphoma
Multiple Myeloma
Plasma Cell Neoplasms
Hodgkin's Lymphoma
Mantle Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lauren W. Veltri specialize in?
Lauren W. Veltri focuses on Lymphoma and Multiple Myeloma. In particular, much of their work with Lymphoma has involved CCND1 positive patients, or patients who are t(11;14) positive.
Is Lauren W. Veltri currently recruiting for clinical trials?
Yes, Lauren W. Veltri is currently recruiting for 4 clinical trials in Morgantown West Virginia. If you're interested in participating, you should apply.
Are there any treatments that Lauren W. Veltri has studied deeply?
Yes, Lauren W. Veltri has studied treatments such as Lenalidomide, Brentuximab Vedotin, Nivolumab.
What is the best way to schedule an appointment with Lauren W. Veltri?
Apply for one of the trials that Lauren W. Veltri is conducting.
What is the office address of Lauren W. Veltri?
The office of Lauren W. Veltri is located at: West Virginia University Healthcare, Morgantown, West Virginia 26506 United States. This is the address for their practice at the West Virginia University Healthcare.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.